KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Cash & Equivalents (2016 - 2025)

Elevance Health (ELV) has disclosed Cash & Equivalents for 17 consecutive years, with $8.7 billion as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 10.77% to $8.7 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $8.7 billion, a 10.77% increase, with the full-year FY2024 number at $8.3 billion, up 27.0% from a year prior.
  • Cash & Equivalents was $8.7 billion for Q3 2025 at Elevance Health, up from $8.6 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $10.0 billion in Q2 2023 to a low of $4.9 billion in Q4 2021.
  • A 5-year average of $7.6 billion and a median of $7.7 billion in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 51.37% in 2022, then plummeted 34.97% in 2024.
  • Elevance Health's Cash & Equivalents stood at $4.9 billion in 2021, then surged by 51.37% to $7.4 billion in 2022, then dropped by 11.66% to $6.5 billion in 2023, then rose by 27.0% to $8.3 billion in 2024, then rose by 5.13% to $8.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ELV's Cash & Equivalents are $8.7 billion (Q3 2025), $8.6 billion (Q2 2025), and $7.5 billion (Q1 2025).